DEVELOPMENT & EVALUATION OF CAPECITABINE LOADED CHITOSAN NANOBUBBLES

In present research, we presented a new approach for formulating nanosized, Capecitabine bubbles by incorporation into chitosan shelled nanobubbles. The effect of amount of capecitabine, amount of chitosan, amount of Epikuron 200, amount of palmitic acid and stirring speed, on percent encapsulation efficiency and drug load while maintain minimum particle size of nanobubbles as studied by definitive screening design. About 13 experiments were randomly arranged by Design Expert® software and statistically analyzed by multiple regression analysis. The optimized formulation obtained using numerical optimization technique by setting restrictions on the response parameters. The three optimized (Batch1-Batch3) formulations were evaluated.The results reveal that the superficial morphology and core-shell structure of nanobubbles was in the size range of 163.18 – 172.54 nm with an encapsulation efficiency of 70.32-71.12 % and loading capacity of 21.18-22.12%. In vitro release profile of capecitabine from nanobubbles with ultrasound show that amount of drug released from nanobubbles was significantly higher (99.85%) than that from the capecitabine suspension within 24h. A requirement for parenteral administration is that the formulation be non-toxic. A requirement for parenteral administration is that the formulation be non-toxic. The hemolytic activity of the blank nanobubbles and capecitabine-loaded nanobubbles was measured to assess their safety. Up to a concentration of 10 mg/ml, aqueous suspensions of chitosan nanobubbles were found to be non?hemolytic. With erythrocytes, drug-loaded nanobubbles had a good safety profile. The results have shown that the nanobubbles were better apposite for contrast enhanced tumor imaging and subsequent therapeutic delivery.